Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CssBA Vaccine with dmLT for ETEC
NCT03404674Phase 1Completed
- Sponsor
- PATH
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of CssBA in enterotoxigenic Escherichia coli infection (6 arms), sponsored by PATH. Primary endpoints: Number of Participants With Solicited Adverse Events and Number of Participants With Unsolicited Adverse Events. Started Jan 2018; status: completed.
02
Drugs
CssBA
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT03404674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404674.